

Lisa V Hampson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8652937/publications.pdf>

Version: 2024-02-01

24
papers

797
citations

933447

10
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

1588
citing authors

#	ARTICLE	IF	CITATIONS
1	Comment on “Biostatistical Considerations When Using RWD and RWE in Clinical Studies for Regulatory Purposes: A Landscape Assessment” Statistics in Biopharmaceutical Research, 2023, 15, 23-26.	0.8	5
2	A New Comprehensive Approach to Assess the Probability of Success of Development Programs Before Pivotal Trials. Clinical Pharmacology and Therapeutics, 2022, 111, 1050-1060.	4.7	7
3	Eliciting judgements about dependent quantities of interest: The SHEffield ELicitation Framework extension and copula methods illustrated using an asthma case study. Pharmaceutical Statistics, 2022, 21, 1005-1021.	1.3	4
4	Improving the assessment of the probability of success in late stage drug development. Pharmaceutical Statistics, 2022, 21, 439-459.	1.3	7
5	Study to evaluate the optimal dose of remifentanyl required to ensure apnea during magnetic resonance imaging of the heart under general anesthesia. Paediatric Anaesthesia, 2021, 31, 548-556.	1.1	2
6	A quantitative framework to inform extrapolation decisions in children. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 515-534.	1.1	2
7	Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma. BMJ Open, 2019, 9, e025877.	1.9	23
8	A phase I trial of the $\hat{\beta}$ -secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 793-801.	6.4	90
9	Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine, 2018, 16, 29.	5.5	398
10	Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods. Statistical Methods in Medical Research, 2018, 27, 398-413.	1.5	33
11	A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment. Statistical Methods in Medical Research, 2018, 27, 3612-3627.	1.5	11
12	Choosing the target difference and undertaking and reporting the sample size calculation for a randomised controlled trial “the development of the DELTA2 guidance. Trials, 2018, 19, 542.	1.6	7
13	Asymmetric inner wedge group sequential tests with applications to verifying whether effective drug concentrations are similar in adults and children. Statistics in Medicine, 2017, 36, 426-441.	1.6	0
14	Aquatic therapy for boys with Duchenne muscular dystrophy (DMD): an external pilot randomised controlled trial. Pilot and Feasibility Studies, 2017, 3, 16.	1.2	10
15	Choosing the target difference (“effect size”™) for a randomised controlled trial - DELTA2 guidance protocol. Trials, 2017, 18, 271.	1.6	10
16	Bayesian survival analysis in clinical trials: What methods are used in practice?. Clinical Trials, 2017, 14, 78-87.	1.6	18
17	Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibility randomised controlled trial and mixed-methods process evaluation. Health Technology Assessment, 2017, 21, 1-120.	2.8	14
18	Designing multi-arm multi-stage clinical trials using a risk-benefit criterion for treatment selection. Statistics in Medicine, 2016, 35, 522-533.	1.6	7

#	ARTICLE	IF	CITATIONS
19	Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation. <i>CNS Drugs</i> , 2016, 30, 1011-1017.	5.9	17
20	Optimizing the data combination rule for seamless phase II/III clinical trials. <i>Statistics in Medicine</i> , 2015, 34, 39-58.	1.6	8
21	Elicitation of Expert Prior Opinion: Application to the MYPAN Trial in Childhood Polyarteritis Nodosa. <i>PLoS ONE</i> , 2015, 10, e0120981.	2.5	32
22	Bridging the gap: a review of dose investigations in paediatric investigation plans. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 898-907.	2.4	12
23	Bayesian methods for the design and interpretation of clinical trials in very rare diseases. <i>Statistics in Medicine</i> , 2014, 33, 4186-4201.	1.6	74
24	Incorporating prognostic factors into causal estimators: A comparison of methods for randomised controlled trials with a time-to-event outcome. <i>Statistics in Medicine</i> , 2012, 31, 3073-3088.	1.6	5